REPLIGEN CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
REPLIGEN CORP (RGEN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$3.24 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2017-02-23
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-12-31 was $75.00K, a 96.19% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-09-30 was -$675.00K, a 387.98% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-06-30 was -$4.65M, a 703.56% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2016-03-31 was $2.00M, a 80.68% increase year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was -$3.24M, a 179.40% decline from fiscal 2015.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was $4.08M, a 97.06% increase from fiscal 2014.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2014 was $2.07M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2016-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$600.00K derived: sum of 2 quarters · filed 2017-02-23 | -$5.25M derived: sum of 3 quarters · filed 2017-02-23 | -$3.24M 10-K · filed 2017-02-23 |
| 2016-09-30 | -$675.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$5.32M derived: sum of 2 quarters · filed 2016-11-03 | -$3.32M 10-Q · filed 2016-11-03 | -$1.35M derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | -$4.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$2.64M 10-Q · filed 2016-08-04 | -$673.00K derived: sum of 3 quarters · filed 2016-08-04 | -$438.61K derived: sum of 4 quarters · filed 2016-08-04 |
| 2016-03-31 | $2.00M 10-Q · filed 2016-05-05 | $3.97M derived: sum of 2 quarters · filed 2016-05-05 | $4.21M derived: sum of 3 quarters · filed 2016-05-05 | $4.98M derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $2.20M derived: sum of 2 quarters · filed 2016-02-25 | $2.97M derived: sum of 3 quarters · filed 2016-02-25 | $4.08M 10-K · filed 2016-02-25 |
| 2015-09-30 | $234.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.00M derived: sum of 2 quarters · filed 2015-11-05 | $2.11M 10-Q · filed 2015-11-05 | $4.07M derived: sum of 4 quarters · filed 2015-11-05 |
| 2015-06-30 | $769.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.88M 10-Q · filed 2015-08-06 | $3.84M derived: sum of 3 quarters · filed 2015-08-06 | |
| 2015-03-31 | $1.11M 10-Q · filed 2015-05-08 | $3.07M derived: sum of 2 quarters · filed 2015-05-08 | ||
| 2014-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $2.07M 10-K · filed 2015-03-17 | ||
| 2014-09-30 | $112.62K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |